Key facts
| Price (PPV) | 457 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | glycopyrronium |
| Class | Drugs for obstructive airway diseases |
| ATC code | R03BB06 |
| Manufacturer | NOVARTIS PHARMA MAROC |
| Presentation | Inhalateur et 30 gélules |
| Nature | Médicament |
| Hospital price | 303 MAD |
| Data collected on | 9/8/2026 |
Indications
Seebri Breezhaler est indiqué dans le traitement bronchodilatateur d'entretien administré une fois par jour pour atténuer les symptômes de patients atteints de bronchopneumopathie chronique obstructive (BPCO). Source : Compendium.ch - Date : 20 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About Seebri Breezhaler 50 µg
Seebri Breezhaler 50 µg belongs to the drugs for obstructive airway diseases therapeutic class. In Morocco, this drug is marketed by NOVARTIS PHARMA MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Seebri Breezhaler 50 µg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Seebri Breezhaler 50 µg
Answers to common questions from Moroccan patients about this drug.